Mushrooms Inc (OTC:MSRM) Announces
Full Patent Filing for Groundbreaking Mycelium Technology Providing
Bacterial Detection and Nutrient Delivery.
Estero,FL -- October 18, 2023 -- InvestorsHub
NewsWire -- Mushrooms Inc.,
(OTC:
MSRM) a leader in mycelium research and development, proudly
announces the successful filing of its non-provisional patent,
titled "METHOD OF GENERATING MULTIFUNCTIONAL MYCELIUM PRODUCTS".
This revolutionary patent showcases a unique approach to bacterial
detection and nutrient delivery, marking a significant shift from
the company's previous provisional filing.
Kimberly Carlson,
CEO of MSRM, remarked, "With the Phase 1 plan for our patent, we
are channeling our efforts into a medical bandage equipped with
real-time bacterial detection. This represents a monumental leap in
healthcare innovation. Beyond just pinpointing infections early,
our aim is to redefine how we engage with, monitor, and tackle
bacterial infections. The implications are profound: early
detection means prompt intervention, potentially averting
complications, and halting outbreaks in their tracks. Imagine a
bandage that changes colors to alert doctors to infections before
they become serious while steadily releasing essential nutrients to
improve health. This has the potential to be the next frontier in
proactive and integrated healthcare."
Dr. Hyder Ali
Khoja, the senior lead scientist on the project, added,
"The Fungal Kingdom has
unlimited magnitude to offer humans, some are even novel biological
benefits which are strengthening the healing power it brings to us.
It has existed for over a billion years accumulating enormous
therapeutic potential. Our patent pending method is not just
an evolution but a revolution in mycelium applications. We are
working with this ancient knowledge to bridge time and technology
for the betterment of our world."
Maqsad Suriev, lead
chemist on the project, shared, "It is a fascinating phenomenon of
materials sciences and we have been fortunate enough to harness the
power of mycelium to create multifunctional products, including
those used to detect the presence of bacteria and deliver essential
nutrients. This breakthrough not only enhances medical intervention
but has the potential to save countless lives through early
detection of infections."
Donald Steinberg,
board director of MSRM, emphasized the broader implications:
"Beyond the immediate applications which are incredibly powerful,
our technology represents a paradigm shift in textiles and product
development. This is the future, and Mushrooms Inc is paving the
way."
Mushrooms Inc's
non-provisional patent centers around methods that generate
multifunctional mycelium products capable of bacterial detection
and nutrient delivery. With applications spanning healthcare,
aerospace, lifestyle, and more, this technology is set to make
significant inroads across various industries.
In the near future,
Mushrooms Inc plans to delve deeper into its business plan,
highlighting its phase 1 product launch— a revolutionary bandage
equipped with real-time bacterial detection. This unveiling
promises to offer a more detailed insight into how the company
envisions bringing this pioneering technology to the medical world
and beyond.
The newly filed
patent, stands independent of the provisional patent, embodying the
collective intelligence and innovative contributions of four
esteemed inventors: Kimberly Carlson, Dr. Hyder Ali Khoja, Maqsad
Suriev, and Donald Steinberg.
Mushrooms Inc
extends its gratitude to its dedicated team, partners, and
supporters. Their commitment to innovation, combined with a
relentless pursuit of excellence, has positioned the company at the
forefront of mycelium technology development.
About Mushrooms Inc.
Mushrooms Inc.
(OTC:
MSRM) is a publicly traded company on the OTC Markets with the
stock symbol MSRM and is the first industrial mushroom company to
be listed on a public exchange. Mushrooms Inc. is a pioneering
biotech company, deeply entrenched in the world of mycology. Our
primary mission is to harness the transformative potential of
Mycelium, especially for groundbreaking applications in the
healthcare sector. Our dedicated R&D endeavors are underpinned
by advanced technology, ensuring rigorous testing and validation of
the manifold health benefits of mushrooms, thereby leading to the
formulation of scientifically-backed supplements.
Our recent patent
underscores our innovation-driven ethos, detailing novel methods
for bacterial detection and nutrient delivery using mycelium. This
patent stands as a testament to our commitment to intertwining
age-old wisdom with contemporary technological advancements, aiming
to revolutionize healthcare interventions and amplify overall
well-being.
Inspired by the
vision and resilience of mycology pioneers, Mushrooms Inc.
establishes robust partnerships, resulting in products that
champion both human health and environmental sustainability.
Safe Harbor Statement
This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about
future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which
they are based are reasonable, we can give no assurance or
guarantee that such
expectations and
assumptions will prove to have been correct. Forward-looking
statements are generally identifiable by the use of words like
"may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of
these words or other variations on these words or comparable
terminology. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject
to numerous factors and uncertainties, including but not limited
to: adverse economic conditions, competition, adverse federal,
state and local government regulation, international governmental
regulation, inadequate capital, inability to carry out research,
development and commercialization plans, loss or retirement of key
executives and other specific risks. To the extent that statements
in this press release are not strictly historical, including
statements as to revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
financial conditions, events conditioned on stockholder or other
approval, or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
Corporate Contact:
CEO: Kimberly
Carlson
Tel: (877)
379-5400
email: info@mushroomsinc.com
Mushrooms (PK) (USOTC:MSRM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Mushrooms (PK) (USOTC:MSRM)
Historical Stock Chart
From Nov 2023 to Nov 2024
